PROCEPT BioRobotics Reports First Quarter 2025 Financial Results

PROCEPT BioRobotics Corporation, a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, has released its unaudited financial results for the first quarter of 2025. The company has also increased its revenue guidance for the full year 2025.

Financial Highlights

For the first quarter of 2025, PROCEPT BioRobotics reported total revenue of $69.2 million, marking a 55% increase compared to the same period in 2024. The U.S. revenue was $60.3 million, a 50% growth from the prior year period, driven primarily by system sales to new hospital customers and increased handpiece revenue. The company reported a net loss of $24.7 million, an improvement from the $26.0 million loss in the first quarter of 2024. Adjusted EBITDA was a loss of $15.8 million, compared to a loss of $20.4 million in the prior year period.

Business and Operational Highlights

During the first quarter of 2025, PROCEPT BioRobotics sold 43 new robotic systems in the U.S. and reported U.S. handpiece and consumables revenue of $38.0 million, a 61% increase from the prior year period. The company also saw significant growth in international revenue, which increased by 104% to $8.9 million. The gross margin for the quarter was 64%, up from 56% in the prior year period, due to improved operational efficiencies and higher average selling prices on U.S. robotic systems.

Strategic Initiatives and Corporate Developments

PROCEPT BioRobotics has increased its fiscal year 2025 total revenue guidance to $323 million, representing a 44% increase compared to the prior year. The company expects a full-year gross margin of approximately 64.5%, with potential headwinds from global tariff rates. Operating expenses for the full year 2025 are projected to be approximately $300 million, with an Adjusted EBITDA loss of $35 million.

Management's Perspective

Reza Zadno, Chief Executive Officer, commented on the strong performance in the first quarter, highlighting the robust procedural momentum and the successful U.S. launch of the Hydros™ system. Zadno emphasized the strategic importance of Aquablation® therapy for leading health systems, noting that approximately 45% of U.S. system placements came from corporate Integrated Delivery Networks (IDNs).

Future Outlook

Looking ahead, PROCEPT BioRobotics projects full-year 2025 revenue to be $323 million, with a gross margin of approximately 64.5%. The company remains confident in its growth trajectory and strategic initiatives, despite potential challenges from global tariff rates.

SEC Filing: PROCEPT BioRobotics Corp [ PRCT ] - 8-K - Apr. 24, 2025